Company Overview: Soligenix

Industry News

4 May

Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO

Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will be presenting preclinical data from three of its biodefense programs at the upcoming Chemical and Biological Defense Science...

Read more

9 Apr

Soligenix Inc.’s CEO Christopher Schaber Interviewed by The Life Sciences Report

Orphan diseases associated with inflammation present excellent development opportunities for small biopharmaceutical companies and their investors. Additionally, inflammatory conditions can result from treatment with cancer therapeutics. The crossover between inflammation and oncology, coupled with vaccine programs of high strategic value, have allowed Soligenix Inc.(OTCQB: SNGX) to build a significant...

Read more

24 Mar

Soligenix Announces Recent Accomplishments and Year-End 2014 Financial Results

Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent accomplishments and financial results for the year ended December 31, 2014. Christopher J. Schaber, PhD, President and Chief Executive Officer...

Read more

11 Mar

Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine

Potential Human Immunogenicity Correlates Identified Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating complete protection and immunogenicity of its ricin vaccine, RiVax™, in...

Read more

5 Mar

Soligenix to Present at the 27th Annual ROTH Conference

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at...

Read more

3 Mar

Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Study to Enroll 20 More Subjects Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has received a positive recommendation from the Data Review Committee (DRC) to continue enrolling...

Read more

2 Mar

SNGX: Updated Preclinical Data on RiVax Presented

Soligenix (SNGX) presented new preclinical studydata that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax™) in a non-human primate (NHP) lethal aerosolized ricin exposure model.  The data was presented in a poster session at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research...

Read more

13 Feb

Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Heat Stable Ricin Toxin Vaccine Elicits Strong Immune Responses and Protects Animals from Ricin Intoxication Soligenix, Inc.  (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address